Matches in Nanopublications for { ?s ?p "DDI between Zolmitriptan and Moclobemide - The MAO inhibitor, moclobemide, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing moclobemide are contraindicated. [drugbank_resource:DB00315_DB01171]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00315_DB01171 label "DDI between Zolmitriptan and Moclobemide - The MAO inhibitor, moclobemide, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing moclobemide are contraindicated. [drugbank_resource:DB00315_DB01171]" assertion.